Page 10 - Forefront Analytics News Today

Forefront Analytics LLC increased its stake in iShares Global REIT ETF (NYSEARCA:REET – Free Report) by 18.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 14,744 shares of the company’s stock after purchasing an additional 2,313 shares during the quarter. Forefront Analytics LLC’s […]

Jaffetilchin Investment Partners LLC cut its stake in shares of iShares Floating Rate Bond ETF (BATS:FLOT – Free Report) by 62.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 105,831 shares of the company’s stock after selling 174,469 shares during the period. Jaffetilchin Investment Partners […]

ALX Oncology Holdings Inc. (NASDAQ:ALXO – Free Report) – Investment analysts at Lifesci Capital issued their Q3 2023 earnings estimates for shares of ALX Oncology in a report released on Friday, August 11th. Lifesci Capital analyst S. Slutsky anticipates that the company will earn ($0.79) per share for the quarter. Lifesci Capital has a “Outperform” […]

Mereo BioPharma Group plc (NASDAQ:MREO – Get Free Report) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 6,200,000 shares, a decline of 19.5% from the July 15th total of 7,700,000 shares. Based on an average daily volume of 1,830,000 […]

Oppenheimer restated their outperform rating on shares of Orchard Therapeutics (NASDAQ:ORTX – Free Report) in a research report released on Wednesday morning, Benzinga reports. They currently have a $34.00 target price on the stock. Separately, Cantor Fitzgerald restated an overweight rating on shares of Orchard Therapeutics in a report on Monday, May 15th. Get Our […]

Chardan Capital restated their buy rating on shares of Achilles Therapeutics (NASDAQ:ACHL – Free Report) in a research note published on Monday morning, Benzinga reports. They currently have a $11.00 target price on the stock. Chardan Capital also issued estimates for Achilles Therapeutics’ FY2024 earnings at ($1.58) EPS. Achilles Therapeutics Trading Up 2.0 % NASDAQ […]

Seven Springs Wealth Group LLC grew its stake in iShares Floating Rate Bond ETF (BATS:FLOT – Free Report) by 2.6% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 169,146 shares of the company’s stock after acquiring an additional 4,356 shares during the period. iShares Floating Rate […]

Laurel Wealth Advisors LLC trimmed its position in iShares Floating Rate Bond ETF (BATS:FLOT – Free Report) by 31.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,514 shares of the company’s stock after selling 2,563 shares during the quarter. Laurel Wealth Advisors […]

Kanawha Capital Management LLC decreased its position in iShares Floating Rate Bond ETF (BATS:FLOT – Free Report) by 11.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,626 shares of the company’s stock after selling 4,625 shares during the quarter. Kanawha Capital […]

Live Oak Private Wealth LLC lessened its holdings in iShares Floating Rate Bond ETF (BATS:FLOT – Free Report) by 93.4% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,020 shares of the company’s stock after selling 56,466 shares during the period. Live Oak Private Wealth LLC’s […]